Postherpetic neuralgia.
Wareham
David
D
Queen Mary University of London & Barts & The London NHS Trust, London, UK.
D015075:2-Aminopurine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000212:Acyclovir / Q000627:therapeutic use; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000588:Amines / Q000627:therapeutic use; D000639:Amitriptyline / Q000627:therapeutic use; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D000077595:Famciclovir; D000077206:Gabapentin; D006562:Herpes Zoster / Q000150:complications* / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D007065:Idoxuridine / Q000627:therapeutic use; D009437:Neuralgia / Q000188:drug therapy / Q000821:virology*; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000588:Amines; D018712:Analgesics, Non-Narcotic; D000929:Antidepressive Agents, Tricyclic; D000998:Antiviral Agents; D003509:Cyclohexanecarboxylic Acids; D000639:Amitriptyline; D015075:2-Aminopurine; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D007065:Idoxuridine; D000077595:Famciclovir; D000212:Acyclovir